论文部分内容阅读
目的探讨胸腔积液中可溶性细胞角蛋白19片段(CYFRA21-1)含量对良、恶性胸腔积液鉴别诊断的价值。方法应用免疫放射法检测30例未行治疗的恶性胸腔积液中CYFRA21-1含量,以30例良性疾病为对照组,并与血清中含量比较。结果恶性胸腔积液中CYFRA21-1含量明显高于良性组(P<0.05),阳性率为63.3%,明显高于同组血清的阳性率(46.7%)(P<0.05)。结论胸腔积液中CYFRA21-1的检测对良、恶性胸腔积液的鉴别有较高的价值。
Objective To investigate the value of soluble cytokeratin 19 (CYFRA21-1) in pleural effusion in the differential diagnosis of benign and malignant pleural effusions. Methods Immunohistochemical method was used to detect the content of CYFRA21-1 in 30 untreated malignant pleural effusions. Thirty patients with benign disease were selected as the control group and compared with the serum contents. Results The content of CYFRA21-1 in malignant pleural effusion was significantly higher than that in benign group (P <0.05), the positive rate was 63.3%, which was significantly higher than that in the same group (46.7%) (P <0.05). Conclusion The detection of CYFRA21-1 in pleural effusion is of great value in differential diagnosis of benign and malignant pleural effusions.